


# Frequency of Antibiotic Resistance of *Escherichia coli* and *Klebsiella pneumoniae* by Production of TOHO-Type $\beta$ -Lactamases at Saint Camille Hospital, Ouagadougou (Burkina Faso)

Serge Sougué<sup>1,2</sup>, Amana Mètuor-Dabiré<sup>1,3</sup>, Djénéba Ouermi<sup>1,4</sup>,  
Yasmine Rahimatou Wend-Kouni Tiemtoré<sup>1</sup>, Bénao Stéphanie Lynseh Carine Sita<sup>1\*</sup> ,  
Théodora Mahoukèdè Zohoncon<sup>1,4</sup>, Yasmine Aminata Bangré<sup>1</sup>, Elie Kabré<sup>2</sup>, Jacques Simporé<sup>1,4</sup>

<sup>1</sup>Department of Biochemistry and Microbiology, Faculty of Applied Science and Technology, Biomolecular Research Centre (CERBA/LABIOGENE), UFR-SVT, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso

<sup>2</sup>National Public Health Laboratory of Ouagadougou, Ouagadougou, Burkina Faso

<sup>3</sup>University of Dedougou, Dedougou, Burkina Faso

<sup>4</sup>Saint Thomas Aquinas University (USTA), Saint Camille Hospital of Ouagadougou, Ouagadougou, Burkina Faso

Email: \*bslcs@icloud.com

**How to cite this paper:** Sougué, S., Mètuor-Dabiré, A., Ouermi, D., Tiemtoré, Y.R.W.-K., Sita, B.S.L.C., Zohoncon, T.M., Bangré, Y.A., Kabré, E. and Simporé, J. (2021) Frequency of Antibiotic Resistance of *Escherichia coli* and *Klebsiella pneumoniae* by Production of TOHO-Type  $\beta$ -Lactamases at Saint Camille Hospital, Ouagadougou (Burkina Faso). *Advances in Microbiology*, 11, 713-722.

<https://doi.org/10.4236/aim.2021.1112051>

**Received:** September 11, 2021

**Accepted:** December 10, 2021

**Published:** December 13, 2021

Copyright © 2021 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

## Abstract

Extended-spectrum  $\beta$ -lactamase (ESBL) appeared some years after the introduction in hospital environment of unhydrolysable or extended-spectrum cephalosporins. Several studies have been reported on the blaTEM, blaCTX-M and blaSHV genes in ESBL producing Enterobacteria, however, very few studies reported in the literature were related to blaCTX-M subgroup blaTOHO. TOHO enzymes were responsible for healthcare-associated infections in hospitals and in the community. In Burkina Faso, data related to these types of enzymes were scarce. The purpose of this study was to detect TOHO enzymes in *Escherichia coli* and *Klebsiella pneumoniae* in order to know the prevalence of infections related to bacterial resistance due to TOHO enzymes at Saint Camille Hospital of Ouagadougou (Burkina Faso). The study was conducted firstly by microbiological identification of ESBLs-producing by *Escherichia coli* and *Klebsiella pneumoniae* using API 20 E gallery; secondly the antibiogram was performed by the diffusion method and finally the molecular characterization was made by conventional PCR to search for the bla-TOHO gene. The visualization of the specific bands was made using the ultraviolet lamp (Gene Flash) for the photography of the gels. Data were entered and analyzed using Excel 2013 and EPI Info version 6.0 software. A

---

p-value < 0.05 was considered as significant. We obtained at all 39 strains constituted by 21 (53.8%) *Escherichia coli* and 18 (46.2%) *Klebsiella pneumoniae*. Molecular characterization showed the presence of the blaTOHO gene in 25 bacterial strains (64.1%). It was therefore established in this study the existence of blaTOHO gene at Saint Camille Hospital in Ouagadougou in Burkina Faso. Our study made it possible to know the distribution of the blaTOHO gene in *Escherichia coli* and *Klebsiella pneumoniae*.

## Keywords

Antibiotic, Resistance, Bacteria, ESBL, Genes, TOHO

---

## 1. Introduction

Antimicrobial resistance became a threat to public health. It constitutes a growing danger to human health in the whole world; but the hospital has always been considered like the most important risk holder [1]. Thereby, the first antimicrobial resistance surveillance data published by the World Health Organization [2] showed high levels of resistance to several serious bacterial infections in both high and low income countries. Antimicrobial resistance is responsible for about 700,000 deaths a year worldwide and has huge implications for the cost of healthcare [3]. The production of Extended-Spectrum  $\beta$ -lactamases (ESBLs) by Enterobacteria is the main mechanism of the antimicrobial resistance. Several studies have been conducted on the major genes involved in the production of ESBLs. The most common ESBLs were the Temoneira (TEM), Variable sulfhydryl (SHV) and Cefotaximase-Munich (CTX-M) types [4]. The first plasmid TEM-1-type  $\beta$ -lactamase was isolated in 1965 in Greece from a strain of *E. coli* isolated in a patient named Temoneira hence his name [5]. The SHV-type ESBL was derived by punctual mutations from the original SHV-1 enzyme, which corresponds to a *K. pneumoniae* chromosomal penicillinase blaSHV gene [6]. Currently, more than 180 SHV ESBLs variants have been described [7]. CTX-M ESBLs were initially described in 1986 in Japan, Germany and France in 1989 (CTX-M-1) and have since spread widely around the world [8]. CTX-M is the most prevalent ESBLs worldwide [9]. The CTX-M group (for cefotaximase) originally gave to Enterobacteria a higher level of resistance to Cefotaxime, Ceftriaxone, Cefepime and Aztreonam than to Ceftazidime [10]. Some of them have evolved more recently by mutation (punctual or not) generating a high level of resistance to Ceftazidime such as CTX-M-15, CTX-M-16, CTX-M-19, CTX-M-23 and CTX-M-32 enzymes [11]. Recently, more than 150 variants of CTX-M have been described and classified into 6 phylogenetic groups: the CTX-M-1 group; CTX-M-2 and Toho-1 group; the CTX-M-8 group; the CTX-M-9 group, the CTX-M-25 group and finally the CTX-M-45 group. These new ESBLs were not closely related to TEM or SHV  $\beta$ -lactamases since they only showed 40% homology with these classic ESBLs [12]. Horizontal dissemination of the genes

coding for the CTX-M enzymes occurs via conjugative plasmids but also via other genetic elements such as integrons and ISEcp1 insertion sequences [1]. Besides the so-called major ESBLs, there were minor types ESBLs such as TOHO-type, BES-type, Pseudomonas extended Resistance (PER) type, Vietnam extended-spectrum  $\beta$ -lactamase (VEB) type, Guiana extended-spectrum  $\beta$ -lactamase (GES) type, TEM Like Activity (TLA) type, Serratia fonticola (SFO) type which were less studied [13]. TOHO-type is a variant of CTX-M2c [14]. The blaTOHO gene has been described for the first time at Toho University School of Medicine (Japan) in the urine of a one-year-old girl in *E. coli* TUH12191 [15]. This gene has been notified in the first time in Argentina in *Shigella flexneri* in the stool of a 33-year-old woman [14]. TOHO-2 ESBLs have also been described as produced by *E. coli* TUH1083. It was categorized as an enzyme similar to TOHO-1 group  $\beta$ -lactamase rather than to mutants of TEM or SHV enzymes [16]. The prevalence of the blaTOHO gene in ESBL-producing by Enterobacteria has not been reported in the literature yet. Investigations work on  $\beta$ -lactamases at Burkina Faso scale were relatively recent and have already identified the presence of TEM, SHV and CTX-M genes, which were responsible for bacterial resistance in Enterobacteria [17]. This study was undertaken with the aim of detecting the blaTOHO gene in ESBLs-producing by *Escherichia coli* and *Klebsiella pneumoniae* at Saint Camille Hospital of Ouagadougou (Burkina Faso).

## 2. Methods

### 2.1. Type of Study

It was a cross-sectional study conducted at Saint Camille Hospital in Ouagadougou (Burkina Faso) from September to November 2018. Samples collected consisted of stool samples, urine samples and vaginal swab samples from hospitalized patients or out-patients. We collected at all 250 samples from 250 patients. This study included samples (stool, urine and urethral swabs) from patients of both sexes who had a stool culture, uroculture or urethral swab culture during the collection period and in whom the bacteria were resistant to Amoxicillin + Clavulanic Acid and at least one 3rd generation cephalosporin or at Aztreonam. We collected samples from all patients who met the selection criteria. Samples were inoculated on common media like Uri Select medium, Hektoen medium and Salmonella Shigella (SS) medium to allow Enterobacteria growth and then incubated for 24 hours at 37°C. Subsequently, Enterobacteria that grew on the previous media were subcultured on a Mueller-Hinton (MH) medium and then incubated for 24 hours at 37°C for antimicrobial analysis [18].

### 2.2. Antimicrobial Essays

The bacterial strains were identified using Analytical Profile Index (API 20 E) Identification method.

Antibiotic susceptibility and resistance test were carried out on Mueller-Hinton (MH) medium with pure colonies of *Escherichia coli* and *Klebsiella pneumoniae*

according to the recommendations of the Committee of antibiogram of the French Society of Microbiology [19]. The antibiotic discs used were: Amoxicillin + Clavulanic acid (Augmentin), Cefotaxime, Ceftazidime, Ceftriaxone and Aztreonam. All Augmentin resistant *Escherichia coli* and *Klebsiella pneumoniae* and at least one third generation cephalosporin were considered to this study as ESBLs producing *Escherichia coli* and *Klebsiella pneumoniae* [20].

## 2.3. Molecular Characterization of ESBLs

### 2.3.1. Bacterial DNA Extraction

The boiling method was used to extract DNAs from bacteria [21]. The strains were reactivated by culturing on the MH medium for 18 - 24 hours. An isolated colony was taken from the Petri dishes and suspended in 200 µl of distilled water previously aliquoted in labeled Eppendorf tubes, then followed by immersion in a water bath at 100°C for 15 minutes to release the genetic material. After immersion in a water bath, the suspension was centrifuged at 12,000 rpm for 10 minutes and the supernatant containing DNA released was transferred to a new Eppendorf tube. The concentration of the DNA was then determined using the Nanodrop-type spectrophotometer (BioDrop UV/V is DUO, Holliston, USA).

### 2.3.2. Molecular Analysis

The reaction medium for PCR was constituted 25 µl volume composed of the Master Mix, the DNA and the primers for blaTOHO. PCR program consisted of an initial denaturation at 95°C for 5 minutes followed by 30 cycles (Denaturation 95°C/59 s, Annealing 50°C/59 s, Elongation 68°C/59 s) and a final Extension at 68°C for 5 minutes. We used Gene Amp Thermocycler PCR System 9700.

PCR amplification of blaTOHO gene was carried out with specific primers provided by Applied Biosystems: TOHO-1A 5'-ATG TGC AGT ACC AGT AA-3' and TOHO-1B 5'-TAG GTC ACC AGA ACC AG-3' for blaTOHO with 876 pb as molecular weight [22].

### 2.3.3. Electrophoresis on Agarose Gel

Agarose gel (1%) for electrophoresis was prepared with 1× TBE buffer with addition of 8 µl Ethidium bromide (BET) 0.5 µg/ml which allowed visualization of the bands in the UV light. An electrophoretic migration at 110 millivolts for 30 minutes was performed on the PCR products using a molecular weight marker (1 kb). The fragments were visualized under UV light (Gene Flash) and the images were recorded [23].

## 2.4. Data Processing


The clinical data was entered in Excel 2013 and then analyzed with the Standard Statistical Package for Social Sciences (SPSS) version 17.0 for Windows and the EPI Info version 6.0 software. All tests of significance were considered statistically significant at p-value < 0.05 [24].

### 3. Results

We have found at total 16 stools samples, 22 urines samples and 1 vaginal swab samples positive to *Escherichia coli* and *Klebsiella pneumoniae*. All samples had shown an antibiotic resistance profile by ESBL production (**Figure 1**). Among them 15 patients were male and 24 were female, with a sex ratio of 0.63. The ages were ranged from 22 days to 95 years with an average age of 38 years. There were 20 hospitalized patients and 19 out-patients.

Results for the sensitivity/resistance of the 39 bacterial isolates to the different antibiotics tested showed that 26 strains (66.7%) were resistant to Cefotaxime, 28 strains (71.8%) were resistant to Ceftriaxone, 25 strains (64.1%) were resistant to Aztreonam and 20 strains (51.3%) were resistant to Ceftazidime as shown in **Table 1**. **Table 2** showed the frequency of *Escherichia Coli* and *Klebsiella pneumonia* involved in bacterial resistance in the study. We notice that all strains were resistant to Amoxicillin + Clavulanic acid (Augmentin®).

Molecular characterization of the ESBLs by PCR revealed that 25 (64.1%) strains isolated from patients at Saint Camille Hospital of Ouagadougou (HOSCO) carried the bla<sub>TOHO</sub> gene as shown by the electrophoresis bands (**Figure 2**).




**Figure 1.** Petri dish representing a synergy image characteristic of ESBL producing by *Escherichia coli* strain.

**Table 1.** Resistance profile of different strains to antibiotics used.

Bacterial strains	% ATM	% CAZ	% CTX	% CTR	% Synergy image
<i>Escherichia coli</i>	33.3 (13/39)	30.8 (12/39)	38.5 (15/39)	38.5 (15/39)	5.1 (2/39)
<i>Klebsiella pneumoniae</i>	30.8 (12/39)	20.5 (8/39)	28.2 (11/39)	33.3 (13/39)	2.6 (1/39)

Legend: ATM = Aztreonam, CTX = Cefotaxime, CTR = Ceftriaxone, CAZ = Ceftazidime.



**Figure 2.** Agarose gel image showing PCR products of blaTOHO genes in identified isolates. Legend: Lane (M) = Molecular Weight Marker (DNA Ladder (1 kb)); Lanes (1 - 9) = Samples; Lane (C<sup>-</sup>) = negative control; Lanes 3, 5 and 9 = positive to blaTOHO gene.

**Table 2.** Distribution of strains involved in bacterial resistance by ESBL production.

Bacterial species	Numbers	Frequency (%)
<i>Escherichia coli</i>	21	53.8
<i>Klebsiella pneumoniae</i>	18	46.2
Total	39	100

#### 4. Discussion

In this report, we mentioned the occurrence of several *Escherichia coli* and *Klebsiella pneumoniae* strains carrying the blaTOHO gene. In order to conduct molecular epidemiology study of blaTOHO gene conventional PCR with electrophoresis on agarose gel has been shown to be useful with their sensibility and specificity. In term of predominance of certain strains responsible of antibiotic resistance, it has been found at Laghouat Hospital (Algeria): 43% *Escherichia coli* and 30% *Klebsiella pneumoniae* [25]. Other studies; that were done at the Charles De Gaulle Paediatric Teaching Hospital (CHUP/CDG) of Ouagadougou (Burkina Faso), showed 47.22% for *Escherichia coli*; 15.55% for *Klebsiella pneumoniae* and 3.33% for *Klebsiella oxytoca* [26].

The types of ESBLs found in these studies were CTX-M, SHV and TEM. The prevalence of ESBLs produced by *Escherichia coli* and *Klebsiella pneumoniae* were also described in South America (45.4% to 51.9%) [27] and Saudi Arabia (55%) [28].

These results confirm that the overall prevalence of ESBLs production by Enterobacteria fluctuates considerably according to the geographical zones, to the countries and to different hospitals. However, the bacterial strains mainly concerned by antibiotic resistance were *E. coli* and *K. pneumoniae* with the high level of ESBLs production [25] [27].

The antibiotic susceptibility profile of the 39 strains tested showed resistance

to most of  $\beta$ -lactams antibiotics. These levels of antibiotic resistance in the study could be explained by the misuse of antibiotics. It is currently proved that the use of antibiotics, including third-generation cephalosporin for therapeutic purposes is the most important risk factor in the development of bacterial resistance [26]. Other types of resistance mechanisms could explain these levels of antibiotic resistance like the modification of the membrane permeability, the modification of the antibiotic target, the metabolic pathway change or the efflux phenomena [29].

The molecular characterization of the 39 bacterial strains by PCR showed the TOHO type ESBLs in 25 (64.1%). TOHO-1 enzymes have been described for the first time in Japan and were structurally very close to CTX-M and were therefore classified among this group [11] [30]. This type of ESBL (CTX-M) was frequently encountered in hospitals [9]. This could explain the high prevalence of TOHO enzymes in our study. The first detection of TOHO-1 outside Japan was reported in a strain of *Shigella flexneri* in the stool of a 33-years-old woman in Argentina [14]. This bacterial strain expressed an enzyme belonging to CTXM2c whose DNA sequencing gave TOHO-1.

There were two types of TOHO enzymes (TOHO-1 and TOHO-2) and their precise prevalence has never been reported in an epidemiological study and the truth of the sequence has been questioned because it was so closely related to CTX-M-2 [31]. TOHO-1 was an ESBL that has achieved efficient activity not only against penicillins but also against third-generation cephalosporins [32]. TOHO-2 was reported in Tokyo (Japan) in *E. coli* isolated from the urine of a  $\beta$ -lactam treated patient [16].

This high prevalence of the blaTOHO gene in our study about antibiotic-resisting bacterial strains could also be explained by a spread of this gene in Africa and at Saint Camille Hospital in Ouagadougou, HOSCO (Burkina Faso).

The limitations of our study were the small sample size, the scope of the study which is limited to one hospital and the gene sequencing which was not performed. A large sample size with expanding the study to others hospitals for example would allow to find more accurate results. In addition, sequencing of the TOHO gene would confirm our finding.

## 5. Conclusions

The objective of this work was to detect *Escherichia coli* and *Klebsiella pneumoniae* producing TOHO-type ESBL at Saint Camille Hospital of Ouagadougou (Burkina Faso).

This study revealed that alongside the CTX-M, TEM and SHV genes, there were other once rare types of ESBL such as TOHO which was a subgroup of CTX-M found in *Escherichia coli* and *Klebsiella pneumoniae*.

This molecular epidemiological study found the blaTOHO gene in 25 bacterial strains (64.1%) carried by patients in hospitals of Burkina Faso and particularly at Saint Camille Hospital of Ouagadougou.

## Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

## References

- [1] Bradford, P.A. (2001) Extended-Spectrum  $\beta$ -Lactamases in the 21st Century: Characterization, Epidemiology and Detection of This Important Resistance Threat. *Clinical Microbiology Reviews*, **14**, 933-951. <https://doi.org/10.1128/CMR.14.4.933-951.2001>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89009>
- [2] World Health Organization (2018) High Levels of Antibiotic Resistance Found Worldwide, New Data Shows. <https://www.who.int/news/item/29-01-2018-high-levels-of-antibiotic-resistance-found-worldwide-new-data-shows>
- [3] Jasovsky, D., Littmann, J., Zorzet, A. and Cars, O. (2016) Antimicrobial Resistance a Threat to the World's Sustainable Development. *Upsala Journal of Medical Sciences*, **121**, 159-164. <https://doi.org/10.1080/03009734.2016.1195900>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967260>
- [4] Sadeeq, U.R., Tariq, A., Ijaz, A., Nazir, A.K., Bo, H. and Jian, G. (2018) The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. *Bio-med Research International*, **2018**, Article ID: 9519718. <https://doi.org/10.1155/2018/9519718>  
<https://www.hindawi.com/journals/bmri/2018/9519718>
- [5] Zubair, M., Malik, A. and Ahmad, J. (2015) Microbiology of Diabetic Foot Ulcer with Special Reference to ESBL Infections. *American Journal of Clinical and Experimental Medicine*, **3**, 6-23. <https://doi.org/10.11648/j.ajcem.20150301.12>  
<http://www.sciencepublishinggroup.com/j/ajcem>
- [6] Hæggman, S., Lofdahl, S., Paauw, A., Verhoef, J. and Brisse, S (2004) Diversity and Evolution of the Class A Chromosomal Beta-Lactamase Gene in *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy*, **48**, 2400-2408. <https://doi.org/10.1128/AAC.48.7.2400-2408.2004>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC434173>
- [7] Liakopoulos, A., Mevius, D. and Ceccarelli, D. (2016) A Review of SHV Extended-Spectrum  $\beta$ -Lactamases: Neglected Yet Ubiquitous. *Frontiers in Microbiology*, **7**, Article No. 1374. <https://doi.org/10.3389/fmicb.2016.01374>  
<https://www.ncbi.nlm.nih.gov/m/pubmed/27656166>
- [8] Thomson, K.S. and Moland, E.S. (2000) The New  $\beta$ -Lactamases of Gram-Negative Bacteria at the Dawn of the New Millennium. *Microbes and Infection*, **2**, 1225-1235. [https://doi.org/10.1016/S1286-4579\(00\)01276-4](https://doi.org/10.1016/S1286-4579(00)01276-4)  
<https://www.ncbi.nlm.nih.gov/pubmed/11008112>
- [9] Paterson, D.L. and Bonomo, R.A. (2005) Extended-Spectrum  $\beta$ -Lactamases: A Clinical Update. *Clinical Microbiology Reviews*, **18**, 657-686. <https://doi.org/10.1128/CMR.18.4.657-686.2005>  
<https://www.ncbi.nlm.nih.gov/pubmed/16223952>
- [10] Arlet, G. and Philippon, A. (2003) Les Nouvelles  $\beta$ -Lactamases à l'aube du troisième millénaire. *Revue Française des Laboratoires*, **2003**, 41-55. [https://doi.org/10.1016/S0338-9898\(03\)80501-2](https://doi.org/10.1016/S0338-9898(03)80501-2)  
<https://www.sciencedirect.com/science/article/abs/pii/S0338989803805012?via%3Di>



[hub](#)

- [11] Bonnet, R. (2004) Growing Group of Extended-Spectrum-Beta-Lactamases: The CTX-M Enzymes. *Antimicrobial Agents and Chemotherapy*, **48**, 1-14. <https://doi.org/10.1128/AAC.48.1.1-14.2004>  
<http://europepmc.org/articles/pmc310187>
- [12] Elhani, D. (2012) Les bêta-lactamases à spectre étendu: Le défi s'accroît. *Annales de Biologie Clinique*, **70**, 117-140. <https://doi.org/10.1684/abc.2012.0686>  
<https://pdfs.semanticscholar.org/223b/d4c5edfb859b0ccfa9d8b20cd57ff84ee08c.pdf>
- [13] Cattoir, V. (2008) Les nouvelles  $\beta$ -lactamases à spectre étendu (BLSE). <https://www.mapar.org/article/1/Communication%20MAPAR/qm6segij/Les%20nouvelles%20b%C3%AAta-lactamases%20%C3%A0%20spectre%20%C3%A9tendu%20%28BLSE%29.pdf>
- [14] Andres, P., Petroni, A. and Faccone, D. (2005) Extended-Spectrum  $\beta$ -Lactamases in *Shigella flexneri* from Argentina: First Report of TOHO-1 outside Japan. *International Journal of Antimicrobial Agents*, **25**, 501-507. <https://doi.org/10.1016/j.ijantimicag.2005.02.016>  
<https://www.ncbi.nlm.nih.gov/pubmed/15878653>
- [15] Ishii, Y., Akira, O. and Hayao, T. (1995) Cloning and Sequencing of the Gene Encoding a Cefotaxime-Hydrolysing Class A  $\beta$ -Lactamase Isolated from *Escherichia coli*. *American Society for Microbiology*, **39**, 2269-2275. <https://doi.org/10.1128/AAC.39.10.2269>  
<https://aac.asm.org/content/aac/39/10/2269.full.pdf>
- [16] Ling, M., Yoshikazu, I. and Masaji, I. (1998) Cloning and Sequencing of Gene Encoding Toho-2, a Class A  $\beta$ -Lactamase Preferentially Inhibited by Tazobactam. *Antimicrobial Agents and Chemotherapy*, **42**, 1181-1186. <https://doi.org/10.1128/AAC.42.5.1181>  
<https://www.ncbi.nlm.nih.gov/pubmed/97105770>
- [17] Zongo, K.J., Dabire, A.M., Compaore, L.G., Sanou, I., Sangare, L., Simpore, J. and Zeba, B. (2015) First Detection of Bla TEM, SHV and CTX-M among Gram Negative *Bacilli* Exhibiting Extended Spectrum  $\beta$ -Lactamase Phenotype Isolated at University Hospital Center, Yalgado Ouedraogo, Ouagadougou, Burkina Faso. *African Journal of Biotechnology*, **14**, 1174-1180. <https://doi.org/10.5897/AJB2014.13908>  
<http://www.ajol.info/index.php/ajb/article/view/116698>
- [18] Gaillot, O., Camillo, P.D., Berche, P., Courcol, R. and Savage, C. (1999) Comparison of CHROMagar Salmonella Medium and Hektoen Enteric Agar for Isolation of Salmonellae from Stool Samples. *Journal of Clinical Microbiology*, **37**, 762-765. <https://doi.org/10.1128/JCM.37.3.762-765.1999>  
<https://www.ncbi.nlm.nih.gov/pubmed/105770>
- [19] Communauté de l'Antibiogramme de la Société Française de Microbiologie (CASFM) (2018) Antibiotic Committee of the French Microbiology Society, Recommendation 2018. [https://www.sfm-microbiologie.org/wp-content/uploads/2019/02/CASFM-V1\\_0-FE\\_V\\_2018.pdf](https://www.sfm-microbiologie.org/wp-content/uploads/2019/02/CASFM-V1_0-FE_V_2018.pdf)
- [20] Amana, M.D., Serge, S., Wend-Kuni, T.R.Y., Mahoukèdè, Z.T., Aminata, B.Y., Paul, O., Elie, K. and Jacques, S. (2019) Coexistence between (TOHO-Type and BES-Type) Extended-Spectrum  $\beta$ -Lactamase Genes of Identified Enterobacteria at Saint Camille Hospital, Ouagadougou, West Africa. *International Journal of Genetics and Molecular Biology*, **11**, 34-40. <https://doi.org/10.5897/IJGMB2019.0181>  
<https://academicjournals.org/journal/IJGMB/article-abstract/A31A5C562415>

- [21] Ribeiro Jr., J.C., Tamanini, R., Soares, B.F., Marangon de Oliveira, A. and Silva, F. (2016) Efficiency of Boiling and Four Other Methods for Genomic DNA Extraction of Deteriorating Spore-Forming Bacteria from Milk. *Agricultural Sciences*, **37**, 3069-3078. <https://doi.org/10.5433/1679-0359.2016v37n5p3069>  
<http://www.uel.br/revistas/uel/index.php/semagrarias/article/view/24630>
- [22] Laurent, P., Isabelle, L.T., Thierry, N., Amal, K. and Patrice, N. (2000) Biochemical Sequence Analyses of GES-1, a Novel Class A Extended-Spectrum  $\beta$ -Lactamase, and the Class 1 Integron In52 from *Klebsiella pneumoniae*. *Antimicrobial Agents and Chemotherapy*, **44**, 622-632. <https://doi.org/10.1128/AAC.44.3.622-632.2000>  
<https://www.ncbi.nlm.nih.gov/pubmed/10681329>
- [23] Lee, P.Y., Costumbrado, J., Hsu, C.Y. and Kim, Y.H. (2012) Agarose Gel Electrophoresis for the Separation of DNA Fragments. *Journal of Visualized Experiments* No. 62, Article No. e3923. <https://doi.org/10.3791/3923>  
<https://www.ncbi.nlm.nih.gov/pubmed/22546956>
- [24] World Health Organization (2019) Instructions for Data-Entry and Data-Analysis Using Epi Info™. [https://www.who.int/gpsc/5may/epi\\_info\\_instructions.pdf](https://www.who.int/gpsc/5may/epi_info_instructions.pdf)
- [25] Lagha, N. (2015) Antibiotic Resistance Study of Extended Spectrum  $\beta$  Lactamase-Producing Enterobacteriaceae (ESBL) Isolated from Laghouat Hospital: Alger. <http://dspace.univ-tlemcen.dz/bitstream/112/7203/1/LAGHA-n.pdf>
- [26] Mètuor-Dabiré, A. (2014) Molecular and Kinetic Characterization of Broad-Spectrum  $\beta$ -Lactamase (ESBL) Types of Bacterial Strains Collected at the Pediatric University Hospital Charles De Gaulle (CHUP-CDG): Ouagadougou. [http://www.labiogene.org/IMG/pdf/these\\_metuor\\_dabire\\_amana\\_corrige2.pdf](http://www.labiogene.org/IMG/pdf/these_metuor_dabire_amana_corrige2.pdf)
- [27] Villegas, M.V., Kattan, J.N., Quinteros, M.G. and Casellas, J.M. (2008) Prevalence of Extended-Spectrum  $\beta$ -Lactamases in South America. *Clinical Microbiology and Infection*, **14**, 154-158. <https://doi.org/10.1111/j.1469-0691.2007.01869.x>  
<https://www.sciencedirect.com/science/article/pii/S1198743X14604869>
- [28] Al-Agamy, M.H., Shibl, A.M. and Tawfik, A.F. (2009) Prevalence and Molecular Characterization of Extended-Spectrum Beta-Lactamase-Producing *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. *Annals of Saudi Medicine*, **29**, 253-257. <https://doi.org/10.4103/0256-4947.55306>  
<https://www.ncbi.nlm.nih.gov/pubmed/19587523>
- [29] Munita, J.M. and Arias, C.A. (2016) Mechanisms of Antibiotic Resistance. *Microbiology Spectrum*, **4**, 4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888801>
- [30] Tetsuya, Y., Hiroshi, K. and Kazuyoshi, S. (1997). Nosocomial Spread of Cephem-Resistant *Escherichia coli* Strains Carrying Multiple Toho-1-Like  $\beta$ -Lactamase Genes. *Antimicrobial Agents and Chemotherapy*, **41**, 2606-2611. <https://doi.org/10.1128/AAC.41.12.2606>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC164177>
- [31] Hawkey, P.M. (2008) Prevalence and Clonality of Extended-Spectrum  $\beta$ -Lactamases in Asia. *Clinical Microbiology and Infection*, **14**, 159-165. <https://doi.org/10.1111/j.1469-0691.2007.01855.x>  
[https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(14\)60487-0/fulltext](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60487-0/fulltext)
- [32] Tatsuro, S., Akiko, I., Shinya, F., Takayoshi, W., Masaji, I., Ishii, Y. and Hiroshi, M. (2002) Acyl-Intermediate Structures of the Extended-Spectrum Class A  $\beta$ -lactamase, Toho-1, in Complex with Cefotaxim, Cephalothin, and Benzylpenicillin. *The Journal of Biological Chemistry*, **277**, 46601-46608. <https://doi.org/10.1074/jbc.M207884200>  
<http://www.jbc.org/content/277/48/46601.full>